Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.

Saved in:
Bibliographic Details
Title: Trastuzumab-Emtansine and Osimertinib Combination Therapy to Target HER2 Bypass Track Resistance in EGFR Mutation-Positive NSCLC.
Authors: Jebbink M; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Langen AJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Monkhorst K; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boelens MC; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van den Broek D; Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Noort V; Department of Statistics, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Gooijer CJ; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Mahn M; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Wekken AJ; Department of Pulmonology, University of Groningen and University of Medical Centre Groningen, Groningen, The Netherlands., Hendriks L; Department of Pulmonology, MUMC, Maastricht, The Netherlands.; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Hashemi SMS; Department of Pulmonary Medicine, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands., Paats MS; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Dingemans AC; Department of Pulmonary Diseases, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Pulmonary Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Source: JTO clinical and research reports [JTO Clin Res Rep] 2023 Feb 24; Vol. 4 (4), pp. 100481. Date of Electronic Publication: 2023 Feb 24 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3643
DOI:10.1016/j.jtocrr.2023.100481